GlaxoSmithKline migraine headache brand Excedrin continues its everyday headache cultural marketing, agreeing to help pay for a Cleveland Brown's perfect…

Amid tough times at the drugmaker, Teva is launching an exclusive generic to Gilead Sciences' hep B and HIV antiviral Viread.

Eli Lilly is aiming for $23 billion in 2018 revenue, but it'll have to contend with a tough environment in diabetes and one hefty patent expiration.

Roche’s Genentech is out with a new threat to Shire’s hemophilia franchise—but the Dublin drugmaker’s CEO isn’t too concerned.

GlaxoSmithKline may have some new Nucala competition in severe asthma, but it also has a new market all to itself.

Pharma TV ad spending has already officially topped last year with a total of $3.2 billion through the end of November, according to data.

J&J has succeeded in moving Darzalex earlier into multiple myeloma therapy, and it now has data that could help it win a first-line nod.

AbbVie and Roche are working to widen Venclexta’s patient population in previously treated chronic lymphocytic leukemia, and new data should help.